Amin Mirhadi, MD
Dr. Amin Mirhadi is a radiation oncologist at Cedars Sinai Medical Center and the Cedars-Sinai Samuel Oschin Comprehensive Cancer Center in Los Angeles, California. He is part of the multidisciplinary mesothelioma and lung cancer team and also provides his expertise in radiation therapy to the treatment of general pulmonology patients, colon cancer patients, and breast cancer patients.[1]
Dr. Mirhadi has significant expertise in the use of novel radiation approaches and skill in the use of the latest radiation technology for the treatment of challenging malignancies. Among the techniques that he applies is image-guided radiotherapy, which allows him to view the patient’s tumor using a MiniCAT scan in combination with motion management and respiratory gating to allow precise delivery of radiation at an exact point in the respiratory cycle, despite the potential for tumor movement during respiration. He is also skilled in the use of four-dimensional CT scans that show mesothelioma tumors in all phases of the respiratory cycle to inform treatment plans.[5]
Education and Career
Dr. Mirhadi attended medical school at the University of California Irvine School of Medicine. He completed his internship at the Santa Barbara Cottage Hospital and then completed a residency in Radiation Oncology at UCLA Medical Center in Los Angeles.[1]
Professional Memberships and Activities
Dr. Mirhadi is an active member of several professional medical societies and serves or has served on numerous boards and committees in furtherance of excellence in radiation oncology. These include:[2]
- Member, Advisory Committee on the Medical Use of Isotopes
- Los Angeles Radiological Society
- NRC Subcommittee Vice Chair
- Cedars-Sinai Radiation Safety Committee
- Cedars-Sinai Oncology Fellowship Selection Committee
- American Society of Clinical Oncology
- Southwest Skin Cancer Collaborative Group
- Cedars-Sinai Breast Oncology Fellowship Selection Committee
- American Society for Therapeutic Radiation Oncology
- Society of Nuclear Medicine
Research
In addition to his clinical role at Cedars Sinai, Dr. Mirhadi is actively involved in research. His main focus is on how innovations in radiation therapy can improve the treatment outcomes of patients diagnosed with non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma, and other malignancies. He is part of the hospital’s Thoracic Oncology Disease Research Group and has been the recipient of numerous grants and industry contracts in furtherance of his clinical trials and studies, including:[3]
- GRANT – NG-BSP-600-001: Evaluation of the CytoRADxTM System as a Biodosimeter with Human Subjects Receiving Radiation Therapy. ICON Clinical Research Ltd15 Jan 2018 – 29 Sep 2019
- GRANT – A Phase I Trail of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients with Inoperable Stage I Non-Small Cell Lung Cancer. University of California Davis30 Sep 2017 – 29 Sep 2019
- GRANT – A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients with Inoperable Stage I Non-Small Cell. University of California Davis30 Sep 2017 – 29 Sep 2019
- INDUSTRY – A Pilot Phase II open label nonrandomized multi-center study of (F-18) HX4 Positron Emission Tomography (PET) to detect hypoxia in Tumors (F-18)HX4. Siemens Medical Systems
- INDUSTRY – EF-25 METIS: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC). NovoCure Ltd.
- INDUSTRY – IPA-100-206: Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma Biopsy-Only Subjects. Diffusion Pharmaceuticals, LLC
Dr. Mirhadi has also authored and co-authored several articles that have been published in highly respected medical journals, including the following:[4]
- JOURNAL ARTICLE – ASO Visual Abstract: De-Implementation of Low-Value Care in Women ≥ 70 Years with Low-Risk Breast Cancer During the COVID-19 Pandemic. Jan 2024Annals of surgical oncology31(1):389. Co-authorsWang T, Weed C, Tseng J…6 more. 10.1245/S10434-023-14329-Y
- JOURNAL ARTICLE – Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Jan 2024Cancer cell42(1):70-84.e8. Co-authors Shiao SL, Gouin KH, Ing N…30 more. 10.1016/J.CCELL.2023.12.012
- JOURNAL ARTICLE – Use of Radiation Therapy for the Treatment of Breast Cancer in 2019 versus 2020. Dec 2023Advances in Radiation Oncology101435Elsevier BV. Co-authorsPowell AC, Long JW, Bhatnagar AK…2 more 10.1016/J.ADRO.2023.101435
- JOURNAL ARTICLE – Association of Left Anterior Descending Coronary Artery Calcium Progression and Radiation Dose with Major Adverse Cardiac Events in Breast Cancer. Oct 2023International Journal of Radiation Oncology*Biology*Physics117(2):e175Elsevier BV. Co-authorsGasho JO, Silos K, Guthier CV…14 more 10.1016/J.IJROBP.2023.06.1020
- JOURNAL ARTICLE – Lung Cancer Treatment Trends During the Coronavirus Disease 2019 (COVID-19) Pandemic: A Claims and Order Data Analysis (2019-2021). Oct 2023JTO clinical and research reports4(10):100560. Co-authorsPowell AC, Horrall LM, Long JW…2 more. 10.1016/J.JTOCRR.2023.100560
